Clinical trial of Amantadine HCl for hypoxic encephalopathy

Clinical trial of Amantadine HCl for hypoxic encephalopathy - Amantadine HCl for hypoxic encephalopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003160

Enrollment

Registered

2010-02-09

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic encephalopathy

Interventions

Administration of amantadine HCl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients showed neurological deficits following the various causes of hypoxicemia.

Exclusion criteria

Exclusion criteria: The patients, previously showed allergic reactions following amantadine HCl administration.

Design outcomes

Primary

Measure	Time frame
Mini-mental state examination test WAIS-R FIM	—

Secondary

Measure	Time frame
FDG-PET findings	—

Countries

Japan

Contacts

Public ContactTadanori Hamano

University of Fukui Second Department of Internal Medicine

hamano@u-fukui.ac.jp0776-61-3111(2300)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026